Head to Head Contrast: NRx Pharmaceuticals (NASDAQ:NRXP) and Graybug Vision (NASDAQ:GRAY)

NRx Pharmaceuticals (NASDAQ:NRXP) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for NRx Pharmaceuticals and Graybug Vision, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	0	0	1	0	3.00
Graybug Vision	0	0	0	0	N/A

NRx Pharmaceuticals presently has a consensus target price of $43.00, indicating a potential upside of 1,541.22%. Given NRx Pharmaceuticals’ higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Graybug Vision.

Profitability

This table compares NRx Pharmaceuticals and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-260.31%
Graybug Vision	N/A	-77.61%	-71.34%

Volatility & Risk

NRx Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 21.1% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares NRx Pharmaceuticals and Graybug Vision’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	N/A	N/A	-$30.15 million	($3.14)	-0.83
Graybug Vision	N/A	N/A	-$35.60 million	($24.23)	-0.13

NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Summary

NRx Pharmaceuticals beats Graybug Vision on 8 of the 10 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.